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6-OHDA 6-hydroxydopamine
BDNF brain-derived neurotrophic factor
bp base pair
CFLP cleavase fragment length polymorphism
cM centimorgan
cDNA complementary DNA
CNS central nervous system
CNTF ciliary neurotrophic factor
DGGE denaturing gel gradient electrophoresis
DNA deoxyribonucleic acid
E embryonic day
EGF epidermal growth factor
EST expressed sequence tag
FGF fibroblast growth factor
FISH fluorescent in situ hybridization
GDNF glial cell line -derived neurotrophic factor
GFRa GDNF family receptor alpha
HA heteroduplex analysis
kb kilobase pairs
kD kilodalton
Kd dissociation constant
LIF leukemia inhibitory factor
MAPK mitogen activated protein kinase
MEN2 multiple endocrine neoplasia type 2
MPTP 1-methyl-4phenyl-1,2,5,6-tetrahydropyridine
mRNA messenger ribonucleic acid
NGF nerve growth factor
NT neurotrophin
NTN neurturin
p75NTR p75 neurotrophin receptor
PCR polymerase chain reaction
PSP persephin
RFLP restriction fragment length polymorphism
RH radiation hybrid
RNA ribonucleic acid
RT reverse transcription
SSC sodium chloride-sodium citrate
SSCP single strand conformation polymorphism
TGFb transforming growth factor beta
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8SUMMARY
Neurotrophic factors are secreted molecules that are responsible for many functions
in the development, differentiation and survival of mainly neural but also other tissues.
The glial cell line-derived neurotrophic factor (GDNF), a potent survival factor for
the midbrain dopaminergic neurons, was found to signal through a tyrosine kinase
receptor, Ret. This receptor complex includes other, glycosylphosphoinositol-linked
proteins, termed GDNF family receptor alphas (GFRas), that form a family of
homologous molecules involved in the signaling of GDNF and its relatives. GFRa-2
was characterized in this study.
GDNF and Ret are crucial for the development of the kidney and the enteric nervous
system of the digestive tract. GDNF mRNAs were found in the muscularis mucosae
of the developing human colon whereas the cognate receptors were expressed in the
ganglia of the entire digestive tract. In the kidney, GDNF was found to be responsible
for the budding of the ureter from the Wolffian duct.
The gene encoding GDNF was analyzed for mutations in diseases that are closely
linked to the biology of GDNF or its receptors. No disease-associated mutations were
found in the samples from the patients suffering from Hirschsprung’s disease
(aganglionic megacolon), renal aplasia or Parkinson’s disease.
Another important group of neurotrophic factors are called neurotrophins. They all
bind to p75 neurotrophin receptor (p75NTR) and to the different members of the
receptor tyrosine kinases. p75NTR is expressed in the kidney and nervous system, as
well as in non-neuronal cells in some other tissues. The p75NTR gene was analyzed
in the patients of a lethal disorder, Meckel syndrome, with a developmental defect in
the renal, limb and brain morphogenesis. One heterozygous polymorphism was found
and shown not to be the disease mutation. The p75NTR gene was then mapped outside
the Meckel locus.
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Introduction
In embryogenesis, the cells send and re-
ceive signals to develop towards a more
differentiated stage, to divide or to die. The
successful ways to create different func-
tional units, like the neuronal system, have
been conserved in evolution and very simi-
lar mechanisms are responsible for the
development and survival of neurons in
most species from insects to man. These
neuronal differentiation and survival mol-
ecules include the neurotrophic molecules,
some of which are also active in non-neu-
ronal embryonic tissues, or re-activated in
adulthood in tissue renewal or regenera-
tion. In human disease, the neurotrophic
factors and the genes encoding for them
have been studied in various developmen-
tal disorders, birth defects and neurode-
generative diseases.
Like most signaling molecules, the neu-
rotrophic factors can be divided into fami-
lies that are formed of closely related
molecules (Table  1) (Korsching 1993;
Arumäe et al., 1997). A prototypic neu-
rotrophic factor, such as nerve growth fac-
tor (NGF), is a secreted, target-derived
molecule that binds to a transmembrane
receptor (Barbacid 1995; Segal and
Greenberg, 1996) on the cell surface. The
receptor then dimerazes and is activated
by transphosphorylation of the catalytic
intracellular domain, which starts a com-
plex intracellular signaling cascade lead-
ing to immediate, early and late transcrip-
tional changes in the target cell.
Some of the neurotrophic factors are se-
creted, but not derived from a distant tar-
get tissue. These molecules, such as the
ciliary neurotrophic factor (CNTF) have
an auto- or paracrine effect on neuronal
cells. CNTF is structurally related to
cytokines, such as leukemia inhibitory fac-
tor, oncostatin M, interleukin –6,
interleukin –11 and cardiotrophin (Sariola
et al., 1994). Also, some molecules that
are not secreted and have initially been
studied as adhesion molecules have later
been found to mediate neuronal cell dif-
ferentiation, for instance. The integrins
and Eph family of tyrosine kinases are two
types of receptors that are activated by
membrane bound ligands like ELF-1 and
repulsive axon guidance signal (Segal and
Greenberg, 1996).
REVIEW OF THE LITERATURE
Table 1. Families of neurotrophic factors
Neurotrophins
• Nerve Growth Factor (NGF)
• Brain-Derived Neurotrophic Factor (BDNF)
• Neurotrophin 3 (NT3)
• Neurotrophin 4/5 (NT4/5)
Neuropoietins
• Ciliary Neurotrophic Factor (CNTF)
• Leukemia Inhibitory Factor (LIF)
Insulin-like Growth Factors 1-2 (IGF-1, IGF-2)
Transforming Growth Factors
• Transforming Growth Factor a  (TGFa )
• Transforming Growth Factor b  1-3 (TGFb 1,
TGF
b
2, TGF
b
3)
• Glial Cell Line-Derived Neurotrophic Factor
(GDNF)
• Neurturin (NTN)
• Persephin (PSP)
Fibroblast Growth Factors
• Acidic Fibroblast Growth Factor (FGF-1)
• Basic Fibroblast Growth Factor (FGF-2)
• Fibroblast Growth Factor-5 (FGF-5)
Other factors
• Platelet-Derived Growth Factor (PDGF)
• Stem Cell Factor (SCF)
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Figure 1. The target field theory.
A.The axons of neurons grow towards the higher concentration of the trophic factor,
secreted by the target tissue (shaded ellipse).
B. Neurons that succeed to get in contact with the target tissue (gray) are maintained,
but others (white) die.
The NGF family
Neurotrophins
Neurotrophins were originally character-
ized because of their functions in differ-
entiation and survival of neurons, although
many of them are now known to affect
other cell types as well (Levi-Montalcini
1987; Sariola et al., 1994; Barbacid 1995;
Segal and Greenberg, 1996). The first
neurotrophin, NGF, was isolated from
snake venom as early as 1956 based on its
ability to promote the neurite growth of
sympathetic neurons in chicken (Cohen
and Levi-Montalcini, 1956). NGF pre-
vented the neuronal death caused by 6-
hydroxydopamine (6-OHDA) (Levi-
Montalcini et al., 1975), vinblastine or
surgical transectomy (Hendry 1975) of the
postganglionic axons of the superior cer-
vical ganglion. The ability of neurons to
grow axons towards increasing concentra-
tions of NGF (Gundersen and Barrett,
1979; Gundersen and Barrett, 1980) fi-
nally led to the target field hypothesis of
the development of innervation. This
theory (Korsching 1993; Lewin and Barde,
1996) postulates that, as most of the de-
veloping neurons die during embryogen-
esis, their survival is dependent on the
ability of the neuron to compete for the
limited amount of a trophic factor. Neu-
rons that fail to grow axons to the target,
die apoptotically, as shown in Figure 1.
After the discovery of NGF by Levi-
Montalcini and co-workers in the 50s, sev-
eral other members of the NGF family
have been found. The group of
neurotrophins comprises now of the brain-
derived neurotrophic factor (BDNF)
(Barde et al., 1982; Leibrock et al., 1989),
neurotrophin -3 (NT3) (Ernfors et al.,
1990; Hohn et al., 1990; Maisonpierre et
al., 1990) and neurotrophin -4/5 (NT4/5)
(Berkemeier et al., 1991; Hallbook et al.,
1991). Neurotrophin -6 (NT6) has been
found in teleost fish (Götz et al., 1994).
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All neurotrophins (Sariola et al., 1994;
Barbacid 1995; Lewin and Barde, 1996;
Segal and Greenberg, 1996) have similar
biochemical characteristics. They are
synthesized as precursor proteins, then
modified to mature forms, secreted, and
they all act as dimers. Approximately half
of the amino acid residues in the mature
protein are common to all neurotrophins
and they all share six cysteine residues at
identical positions. This leads to the
formation of the disulfide bridges and the
similar tertiary structure of the molecules.
The neurotrophins are able to form stable
heterodimers in vitro (Jungbluth et al.,
1994), although the role of hetero-
dimerization in vivo is not known.
Neurotrophin receptors
The neurotrophins bind to two types of
receptors, tyrosine kinase receptors TrkA,
TrkB or TrkC and a common neurotrophin
receptor p75 (p75NTR) that has no
tyrosine kinase domain (Chao and
Hempstead, 1995; Greene and Kaplan,
1995; Segal and Greenberg, 1996). NGF
binds specifically to TrkA, BDNF and NT-
4/5 to TrkB, and NT-3 to TrkC. In addition
to these specific receptors, all  neuro-
trophins bind to the p75NTR  (Figure 2).
Trk receptors have different splice vari-
ants, some of which lack the catalytic ty-
rosine kinase intracellular domain but the
function of these non-catalytic variants is
not known (Barbacid 1995). The signal
transduction of Trk receptors has been in-
tensively studied and many downstream
target molecules identified (Kaplan and
Miller, 1997).
The p75NTR belongs to the tumor
necrosis factor receptor family and was the
first identified neurotrophin receptor
(Johnson et al, 1986). Although it does not
have a catalytic intracellular tyrosine
kinase domain, it is capable of mediating
the neurotrophin signals. This happens
both by its modulating TrkA signaling and
independently of Trk:s (Kaplan and
Miller, 1997). The ligand binding
Figure 2. The neurotrophin receptors. Preferred receptors are shown with bold arrows,
the dashed arrows show weak interactions. All neurotrophins bind to p75NTR.
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ofp75NTR increases the high-affinity
TrkA binding sites, enhances TrkA
autophosphorylation and selectivity for
neurotrophin ligands. The Trk-indepen-
dent pathway of p75NTR increases
intracellular ceramide levels and further
activates NFkB transcription factor (Carter
et al., 1996) and JNK kinase (Casaccia-
Bonnefil et al., 1996). Conversely, TrkA
activation  inhibits p75NTR-mediated
signaling, but the mechanism of this
inhibition is unclear (Kaplan and Miller,
1997).
Neurotrophins and their
 receptors in development and disease
All neurotrophins stimulate neurite out-
growth and survival of certain neurons or
neural crest cells. The expression pattern
of neurotrophins are only partially over-
lapping, they often affect different subsets
of neurons and show some specific bio-
logical functions (Lewin and Barde, 1996).
The roles of neurotrophins and their re-
ceptors in development have  been ap-
proached by targeted gene disruption
(Table 2).
 Despite severe phenotypes in the periph-
eral nervous system and the high ligand-
receptor phenotype correlation (with some
exceptions), the knockout mice have not
solved the question of the roles of
neurotrophins in the central nervous sys-
tem (CNS) differentiation (Snider 1994;
Barbacid 1995). As most of these mutant
mice die during the first weeks of life,
while the CNS is still developing, the pos-
sible consequences of the disrupted genes
cannot be studied by this approach.  It may
be that the development of the CNS has
been secured with a back-up system that,
for example, allows the different
neurotrophins to compensate for the loss
of each other. We do not know all the func-
tions of neurotrophins and a recent sur-
prising finding is that in contrast to the
well documented survival effects of
neurotrophins, NGF can induce apoptosis
in some neuronal cells (Muragaki et al.,
1997).
Table 2. Main defects observed in the targeted disruptions of neurotrophins and their receptors
(Snider 1994; Barbacid 1995)
Phenotype p75 NGF TrkA BDNF TrkB NT-3 TrkC
Neuronal loss
Sup.cerv.ganglia
Trigeminal ganglia
Nodose-petrosal g.
Vestibular ganglia
Dorsal root ganglia
some
no
no
?
?
yes
severe
95%
70%
no
?
70%
severe
95%
70%
no
?
70%
severe
no
40%
85%
30%
no
severe
no
90%
?
30%
no
marked
50%
60%
40%
20%
65%
marked
25%
?
?
?
20%
Function
Nociception
Balance
Proprioception
partial
normal
normal
low
normal
normal
low
normal
normal
normal
poor
normal
normal
?
normal
normal
normal
poor
normal
normal
poor
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Neurotrophin receptors have been linked
to human diseases. The TrkA gene was
originally found as an oncogene in colon
cancer (Martin-Zanca et al., 1986) and its
translocations are common in papillary
thyroid carcinoma (Bongarzone et al.,
1989).
Recently, a mutation in the TrkA gene was
found to cause congenital insensitivity to
pain with anhidrosis (CIPA) syndrome
(Indo et al., 1996) that closely resembles
the phenotype of the TrkA -deficient mice.
The TrkA and TrkC expression also have
prognostic significance for favorable out-
come in neuroblastoma and medulloblas-
toma, respectively (Nakagawara et al.,
1993; Segal et al., 1994). No disease as-
sociations have been described either for
the TrkB gene, or the genes for p75NTR
or any of the neurotrophins.  The chromo-
somal localizations of the neurotrophin
and their receptor genes are shown in
Table 3.
Table 3. Chromosomal localizations of neurotrophin
and their receptor genes
Gene Human
locus
Reference
NGF 1p22 (Francke et al., 1983)
BDNF 11p13 (Maisonpierre et al., 1991)
NT-3 12p13 (Maisonpierre et al., 1991)
NT-4/5 19q13.3 (Berkemeier et al., 1992)
p75NTR 17q21-q22 (Huebner et al., 1986)
TrkA 1q21-q22 (Weier et al., 1995)
TrkB 9q22.1 (Nakagawara et al., 1995)
TrkC 15q25 (Valent et al., 1997)
GDNF family of
neurotrophic factors
GDNF was found in a classical neuronal
survival approach used in the search for
secreted neurotrophic factors (Lin et al.,
1993). The new, potent neurotrophic
molecule was identified because of the
ability of the conditioned media of glial
cell line cultures to promote the survival
of dopaminergic neurons. Purification and
cloning of GDNF revealed it to be a
member of the transforming growth factor
beta (TGFb) superfamily. Recently, two
new members of the GDNF family,
neurturin (NTN) and persephin (PSP) have
been cloned and characterized (Kotzbauer
et al., 1996; Milbrandt et al., 1998).
Like neurotrophins, also GDNF, NTN and
PSP are first synthesized as precursor
polypeptides and then processed to mature
proteins and secreted (Rosenthal 1997).
They function as disulfide-bonded
homodimers and share the conserved cys-
teine residues of the TGFb superfamily
although the overall amino acid homol-
ogy to TGFb-1, for example, is not more
than 20% (Milbrandt et al., 1998). GDNF,
NTN and PSP are structurally close to
each other and their identity at the amino
acid level is about 40%. They share the
sequence suggesting a common ”cysteine
knot” structure formed by three disulfide
bonds and the potential receptor binding
surfaces have been identified based on the
X-ray crystal structure of GDNF
(Eigenbrot and Gerber, 1997).
In this study we found that the functional
receptor for GDNF is the Ret receptor ty-
14
rosine kinase (I). NTN was later also
shown to signal through Ret (Buj-Bello
et al. 1997, Klein et al. 1997). The recep-
tor complex binding GDNF and NTN is
composed of Ret and a glycosyl-
phosphoinositol-linked GDNF family re-
ceptor alpha (GFRa) protein (Rosenthal
1997). The downstream pathways are
most likely common for all GDNF fam-
ily factors since at least GDNF or NTN
binding to Ret both activate the MAP ki-
nase pathway. The chromosomal loci of
the GDNF family members and their re-
ceptor genes are listed in Table 4.
both isoforms produce the same mature
GDNF, the function of the different splic-
ing is unknown. The human gene has been
mapped to the chromosome 5p12- p13.1
(Schindelhauer et al., 1995) and it has two
coding exons that are more than 10 kb
apart. The full-length GDNF mRNA has
both 5’ and 3’ untranslated regions that
make it up to 4.4 kb long (unpublished
data).
GDNF in the nervous system
GDNF mRNA expression has been ana-
lyzed in many tissues and species by in
situ hybridization (Hellmich et al., 1996;
Suvanto et al., 1996), RNase protection
(Trupp et al., 1995), reverse transcription
polymerase chain reaction (RT-PCR)
(Choi-Lundberg and Bohn, 1995) and het-
erozygous transgenic GDNF- lacZ mice
(Sanchez et al., 1996). GDNF is expressed
in many areas of the CNS during develop-
ment and adulthood. The first expression
site is in the rostral part of the mouse neu-
ral plate at the embryonic day (E)7.5 and
then continues in the anterior neuroecto-
derm until E10.5 (Hellmich et al., 1996;
Suvanto et al., 1996). Thereafter, the ex-
pression becomes more restricted to the
lateral domains of rostral and caudal hind-
brain. Only at late embryonic and newborn
stages, as well as in the adult, is the mRNA
expression seen in the striatum and other
areas of developing dopaminergic system
(Choi-Lundberg and Bohn, 1995; Trupp
et al., 1997).
GDNF specifically affects  cultured
dopaminergic midbrain neurons without
affecting other neurons or glia of substan-
tia nigra (Lin 1996). It increases dopam-
inergic cell number, dopamine uptake, cell
size and neurite length without any change
in g-aminobutyrate acid (GABA) or sero-
tonin uptake or overall number of neurons.
The biological properties and expression
patterns of the GDNF family neurotrophic
factors differ. They all have a neurotrophic
effect on dopaminergic and motoneurons,
but GDNF and NTN also seem to support
peripheral neuronal types. At the moment,
the functions of GDNF are best charac-
terized and will be discussed further.
GDNF gene
The coding region of the GDNF gene is
633 bp encoding for a 211 amino acid pre-
cursor polypeptide from which the mature
GDNF of 134 amino acids is processed
by proteolytic cleavage (Lin et al., 1993).
Another form of alternatively spliced
GDNF mRNA lacking 78 bp in the prepro-
region has also been found (Suter-
Crazzolara and Unsicker, 1994), but since
Table 4. Chromosomal loci of the GDNF
family member and receptor genes
Gene Human
locus
Reference
GDNF 5p12-p13.1 (Bermingham et al., 1995;
Schindelhauer et al., 1995)
NTN 19p13.3 (Heuckeroth et al., 1997)
PSP unknown
Ret 10q11.2 (Ishizaka et al., 1989)
GFR
a
-1 10q26 (Gorodinsky et al., 1997)
GFR
a
-2 8p21-p22 (II)
GFR
a
-3 5q31.1-31.3 (Masure et al., 1998)
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Importantly for the potential clinical use,
GDNF also protects these neurons from
various toxic agents as will be discussed
later with the animal models for
Parkinson’s disease.
GDNF affects motor neurons by both in
vivo and in vitro. In cell culture, 0.1 pg/
ml of GDNF increases motoneuron sur-
vival and cell number, neurite outgrowth
and choline acethyltransferase (ChAT)
activity (Henderson et al., 1994). The
motoneurons can also be rescued from
axotomy-induced or natural cell death by
GDNF in mouse, rat and avian models
(Henderson et al., 1994; Oppenheim et al.,
1995). This response is not limited to de-
veloping motor neurons, but is also seen
in the neurons of adult animals (Li et al.,
1995; Yan et al., 1995) supporting the idea
of the applicability of GDNF as a poten-
tial therapeutic agent in motor neuron dis-
eases, such as amyotrophic lateral sclero-
sis (ALS), spinal muscular atrophy or in
ischemic and mechanic injuries of the spi-
nal cord.
GDNF in the kidney
GDNF mRNA is expressed in the meso-
nephric kidney that later regresses
(Hellmich et al., 1996; Suvanto et al.,
1996). The development of the meta-
nephric, permanent mammalian kidney, is
initiated by a signal from the nephrogenic
mesenchyme that induces the Wolffian
duct to produce the ureteric bud. The ure-
ter then invades the mesenchyme and di-
vides, and its tips induce the condensa-
tion and epithelialization of the adjacent
mesenchyme into excretory tubules
(Saxén, 1987). At that time, GDNF mRNA
is abundantly expressed in the condens-
ing mesenchymal cells around the invad-
ing and branching ureteric bud (Choi-
Lundberg and Bohn, 1995; Hellmich et al.,
1996; Suvanto et al., 1996). The expres-
sion follows the ”nephrogenic zone” of
condensing subcapsular cells and is
downregulated in the differentiated cells
that undergo epithelialization. GDNF
mRNA is expressed also in the precursors
of Sertoli cells in the testis, but not in the
ovaries (Hellmich et al., 1996; Suvanto et
al., 1996).
Already the strictly specific expression
pattern of GDNF during nephrogenesis
suggested a crucial role for it in urogeni-
tal development (Choi-Lundberg and
Bohn, 1995; Hellmich et al., 1996;
Suvanto et al., 1996). This was later veri-
fied through knockout mice experiments
(Moore et al., 1996; Pichel et al., 1996;
Sanchez et al., 1996). The mode of action
of GDNF in the ureter budding is shown
in more detail in this study.
GDNF in other organs
The developing gastrointestinal tract ex-
presses GDNF mRNA from the esopha-
gus to the rectum (Hellmich et al., 1996).
At first, the expression is seen in the un-
differentiated mesenchymal layer that later
on becomes the smooth muscle of the gut
that continuously expresses GDNF tran-
scripts. During development, the expres-
sion of GDNF is also seen in a variety of
other mesenchymal tissues such as limb
buds, cartilage and derivatives of the pha-
ryngeal pouches, although its function in
these sites is not understood (Hellmich et
al., 1996; Suvanto et al., 1996).
Transgenic GDNF –mice
Four different transgenic mice strains have
been constructed to study GDNF function
(Moore et al., 1996; Pichel et al., 1996;
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Sanchez et al., 1996; Nguyen et al., 1998).
Two different GDNF -deficient mouse
strains show reduced number of motoneu-
rons by 20% to 30% in the trigeminal gan-
glia and spinal cord (Moore et al., 1996;
Sanchez et al., 1996). This supports the
hypothesis of GDNF functions as a
muscle-derived survival factor for moto-
neurons that are dependent also on other
factors, like cardiotrophin (deLapeyriere
and Henderson, 1997; Arce et al., 1998).
This effect is verified by the transgenic
mouse line overexpressing GDNF under
the  muscle-specific myogenin promotor
(Nguyen et al., 1998). The neuromuscu-
lar junctions of these mice are
hyperinnervated for several weeks after
birth in GDNF expression-dependent
manner, suggesting that the normally oc-
curring cell death is delayed.
The development of the dopaminergic
neurons in GDNF null mice is not abnor-
mal (Moore et al., 1996; Sanchez et al.,
1996), possibly, because the homozygous
mice die on the first postnatal day before
the maturation of the dopaminergic sys-
tem. No defects have been observed in the
number of tyrosine hydroxylase-positive
dopaminergic neurons in the A9-A10
brain regions where dopaminergic neurons
develop or in the floorplate, the striatum
or the basal ganglia. Also, the neurons
within the locus coeruleus, a noradrener-
gic nucleus severely impaired in
neurodegenerative diseases, show no loss
in cell number although they have been
shown to be GDNF-responsive in chemi-
cal-induced degeneration rescue studies
(Arenas et al., 1995).
Consistent with the observation of GDNF
promoting the survival of chick embry-
onic sensory neurons in vitro, the petro-
sal-nodose, sympathetic superior cervical
and dorsal root ganglia of GDNF -defi-
cient mice show reduction in both cell
number and size (Moore et al., 1996).
However, not all autonomic or sensory
ganglia are affected and, for instance, the
trigeminal sensory and vestibular ganglia
neurons of these animals are intact.
The major phenotypes of the GDNF null
mice are the arrested development of the
metanephric kidney and the enteric ner-
vous system. The GDNF -/- mice have
regularly bilateral renal agenesis (Pichel
et al., 1996). Also the GDNF +/- heterozy-
gous animals frequently show renal abnor-
malities such as unilateral aplasia or dys-
plasia. Morphologically distinct meta-
nephric blastema is present in the mutant
embryos, and the primary defect is the
inability of the ureter to bud from the
Wolffian duct.
The second major functional phenotype of
the GDNF -deficient mice is the peristal-
tic defect of the gut. This is due to the to-
tal absence of neurons in the parasympa-
thetic plexuses of the gastrointestinal tract
below the cardiac stomach. Despite the
strong expression of GDNF in the esopha-
gus, the esophageal neurons develop nor-
mally. At this point it is not clear whether
GDNF is needed for the migration of the
neural crest cells to the gastrointestinal
tract or whether it functions as a support-
ive or differentiation factor for the enteric
neurons.
Ret receptor tyrosine kinase
As shown in this study, the functional re-
ceptor for GDNF is the Ret tyrosine ki-
nase (I). The Ret (REarranged during
Transfection) proto-oncogene was origi-
nally discovered by Takahashi and col-
leagues who showed a novel gene rear-
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rangement and oncogenic activation in a
transfection assay of NIH 3T3 cells with
lymphoma DNA (Takahashi et al., 1985).
The activated gene was then found to code
for a novel tyrosine kinase that has an ex-
tracellular ligand-binding domain with
two cadherin-like repeats, a hydrophobic
transmembrane region and a cytoplasmic
domain with an intrinsic tyrosine kinase
activity. The Ret gene has 21 exons that
span more than 60 kb of genomic DNA
and the mRNA can be alternatively spliced
to produce up to ten protein isoforms
(Myers et al., 1995). The Ret gene has been
assigned to the human chromosome
10q11.2 (Ishizaka et al., 1989).
Ret in development
Ret is expressed during embryogenesis on
various neuronal subsets of the central and
peripheral nervous system, including the
nervous plexuses of the entire intestinal
tract (Pachnis et al., 1993; Watanabe et
al., 1997). Outside the nervous system, Ret
is expressed in the Wolffian duct, budding
ureter and later in the tips of the renal col-
lecting tubules. The expression pattern of
the receptor is in accordance with its
ligand distribution, because in most cases
Ret and GDNF are expressed in adjacent
cells or tissues. In addition to the parallel
expression patterns, a further clue to the
possible interaction between GDNF and
Ret came from the knockout animals. Like
GDNF null mice, also the homozygous
Ret-deficient mice are born alive, but then
die during the first postnatal day because
of renal aplasia or hypodysplasia
(Schuchardt et al., 1994). They also lack
enteric nervous plexuses in both their
small and large bowels. The only major
abnormality in other areas of the nervous
system is the lack of the superior cervical
ganglia (Schuchardt et al., 1994) that are
partially affected in the GDNF null mice,
as well.
Ret signal transduction
The biochemistry downstream of Ret has
been difficult to approach because the
ligand has not been available for use, un-
til recently. Most of this work has there-
fore been done by using the constitutively
active mutant Ret molecules from the can-
cer syndromes, or by using chimeric pro-
teins, like the EGFR ligand binding part
in front of the Ret catalytic domain
(Santoro et al., 1994). Like other tyrosine
kinases, upon ligand binding Ret
autophosphorylates its tyrosine domains
that then serve as docking sites for Src-
homology 2 (SH2) domain containing tar-
get molecules activating different intrac-
ellular pathways. Ret associates with Shc,
Grb2, phospholipase C gamma, Crk, Nck,
and Grb10 proteins (Pandey et al., 1995;
Bocciardi et al., 1997; Ohiwa et al., 1997)
and at least one major pathway shown to
be activated by Ret is the Ras-MAP ki-
nase pathway (Ohiwa et al., 1997; Worby
et al., 1998). Phosphopeptide maps have
showed that the autophosphorylation of
Ret, found in multiple endocrine neopla-
sia (MEN)2B, differs from that of the
wild-type and MEN2A Ret proteins (Liu
et al., 1996), suggesting that also the tar-
gets downstream of them may differ (Zhou
et al., 1995). Some of these targets like
paxillin have now been identified
(Bocciardi et al., 1997).
Ret in human diseases
The gene for Ret is a special disease gene,
since at least five different diseases can
be the result of its mutations. As was
shown by Takahashi et al. in 1985, Ret is
able to transform cells, when translocated.
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Similar gene translocations have been
found in human papillary thyroid carci-
nomas (Grieco et al., 1990), where the ty-
rosine kinase coding domain of Ret gene
is fused with the 5’ sequence of a gene
that is expressed in the follicular cells lead-
ing to ectopic Ret activation. Ret gene
mutations have been described in the
MEN2A and MEN2B hereditary cancer
syndromes, and in medullary thyroid car-
cinoma (Donis-Keller et al., 1993;
Mulligan et al., 1993). In these diseases,
the oncogenic mutations constitutively
activate the phosphorylation of the recep-
tor. For example, the MEN2A mutation
changes one cysteine residue in the extra-
cellular domain of the molecule leading
to the dimerization of the receptor with-
out ligand binding (Santoro et al., 1995).
All the mutations found in the Ret gene
have been recently reviewed (Edery et al.,
1997). The cancer syndromes MEN2A,
MEN2B and familiar medullary thyroid
carcinoma are often referred to as
neurocristopathies, since the affected cells
originate from the neural crest. An addi-
tional neurocristopathy is the
Hirschsprung’s disease or aganglionic
megacolon, which is often caused by an
inactivating Ret mutation, as described
later.
GDNF family receptor alphas
The initial crosslinking experiments with
GDNF (Trupp et al., 1995) showed satu-
ration of GDNF binding in embryonic
chick sympathetic neurons at 1-5 x 10-9
M, that is weaker than the interaction be-
tween most other growth factors and their
receptors, like NGF and Trk (Kaplan et
Figure 3. Binding of GDNF to Ret.
A. GDNF dimer binds to two molecules of GFRa-1 and this complex binds to Ret
that dimerizes.
B. The dimerization of Ret causes the autophosphorylation of the tyrosine residues
of the two subunits.
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al., 1991). Later it was found that the high
affinity GDNF binding to Ret is mediated
through a glycosylphosphoinositol-linked
protein termed the GDNF family receptor
alpha (GFRa, first described as GDNFR-
a) (Jing et al., 1996; Treanor et al., 1996).
The dissociation constant (K
d
) between
GDNF and GFRa was then shown to be
approximately 2x 10-12 M in the trans-
fected 293T cell line. As illustrated in Fig-
ure 3, a dimer of GDNF first binds to two
molecules of GFRa and the GDNF-GFRa
complex binds to and activates Ret. It has
now become apparent that different cell
types show different affinities to GDNF,
which is most likely due to their different
expression pattern of receptors.
The family of GFRas has rapidly ex-
panded, and comprises at the moment
three members from GFRa-1 to GFRa-3
(Jing et al., 1996; Treanor et al., 1996;
Baloh et al., 1997; Jing et al., 1997; Klein
et al., 1997;  Masure et al., 1998;
Naveilhan et al., 1998; Worby et al., 1998,
II). GDNF and NTN seem to prefer GFRa-
1 and GFRa-2, respectively, although they
are able to bind and activate Ret by using
either one of these two a-receptors (Baloh
et al., 1997; Jing et al., 1997). At this stage,
the ligand of GFRa-3 is not known, but it
seems not to be PSP. The expression pat-
terns of the GFRas are both overlapping
and complementary with each other, the
ligands and with the expression of Ret,
which suggests that the biological func-
tions of the GDNF family can be regu-
lated in very many ways, like the choice
of the receptor or the concentration of the
factors.
DEVELOPMENT OF THE ENTERIC NERVOUS SYSTEM
begins with an outgrowth of vagal neural
crest precursor cells, which use the ven-
tral pathway and migrate through the
somites. The first neuroblasts are detect-
able in the proximal foregut of mice at
embryonic day 9.5 (Em9.5) and then pro-
ceed in a cephalo-caudal manner (Kapur
et al., 1992). The vagal progenitors colo-
nize the entire gut reaching the terminal
hindgut by Em13.5, while the progenitors
arising from the truncal and sacral regions
will migrate only to the rostral foregut and
postumbilical bowel, respectively
(Gershon 1997).
The enteric nervous system (ENS) derives
from neural crest precursor cells that mi-
grate and colonize the wall of the intesti-
nal tract during embryogenesis (Le
Douarin and Teillet, 1973). Both experi-
mental and descriptive data show that
three different regions of the neural crest
- vagal, truncal and sacral - contribute to
the precursors of intestinal neuroblasts and
Schwann cells, and that the different re-
gions of the neural crest give rise to the
neuroblasts colonizing distinct regions of
the gut (Serbedzija et al., 1991; Durbec et
al., 1996; Gershon 1997). The migration
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Neural crest chimeras between chicken
and quail have revealed that the precur-
sors for the intestinal nervous plexus mi-
grate from the neural crest as single cells
or small cell clusters and, in the front of
the migration, intermingle with the mes-
enchymal cells of the intestinal wall (Le
Douarin and Teillet, 1973). They later
become redistributed in the presumptive
Auerbach (intermuscular) and Meissner
(submucosal) plexuses, when the muscu-
lar layers of the gut begin to differentiate.
The migrating neuroblasts are still capable
of differentiating into various types of
neural cells, as shown by the tissue trans-
plantation experiments of various re-
searchers (Rothman et al., 1990; Lo and
Anderson, 1995). The developmental op-
tions of the precursor cells become pro-
gressively restricted during the innerva-
tion process when the cells migrate in a
certain microenvironment, but the mecha-
nisms determining the fate of the intesti-
nal nerves are not yet known.
 GDNF signaling pathway in the devel-
oping gut
The mice deficient for GDNF lack the
enteric nerves distal to the cardiac stom-
ach (Pichel et al., 1996), which indicates
that GDNF is crucial at some point dur-
ing the enteric nervous system develop-
ment. The function of GDNF in the en-
teric innervation is supported by the ex-
pression data. By in situ hybridization,
RNase protection assay and RT-PCR stud-
ies GDNF mRNA has been found in the
intestinal muscle layers from esophagus
to rectum in embryonic mice and rats
(Choi-Lundberg and Bohn, 1995;
Hellmich et al., 1996; Suvanto et al.,
1996). In addition, at least rat stomach and
small intestine continuously express
GDNF mRNA after birth to adulthood
(Choi-Lundberg and Bohn, 1995).
Ret, the functional receptor for GDNF, is
expressed in the migrating enteric
neuroblasts already during their early de-
velopment (Pachnis et al., 1993). These
enteric neuroblasts in Ret-deficient mice
undergo apoptosis soon after they reach
the level of the duodenum (Durbec et al.,
1996). Because Ret- and GDNF-deficient
mice show similar defects in ENS, GDNF
has been thought to be a signal conduct-
ing the ENS precursor cells to the right
direction and position in the intestine.
Prior to this study, no data have been re-
ported for the mRNA distribution of
GDNF in human intestine. However,
GDNF protein has been studied in normal
colon as well as in affected and healthy
colonic segments of the aganglionic mega-
colon i.e. Hirschsprung’s disease patients
by immunohistochemistry and immunoas-
say (Bär et al., 1997). GDNF-like immu-
noreactivity was found in the neural fiber-
like structures in the gut, and there were
no differences in GDNF levels between
the ganglionic and aganglionic segments
of Hirschsprung’s disease patients. The
ganglionic expression of Ret protein has
been demonstrated in human embryonic
and newborn intestine by immunohis-
tochemical studies (Martucciello et al.,
1995; Tam et al., 1996). In addition to
GDNF and Ret, GFRa-1 and GFRa-2 are
expressed in mouse gut, but no data on
the alpha receptors in human development
had been previously reported.
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NEUROTROPHIC FACTORS AND THEIR RECEPTORS
IN HUMAN DISEASES
gives good or fairly good result in most of
the patients (Langer et al., 1996;
Heikkinen et al., 1997). The choice and
result of different surgical protocols  de-
pends on the age of the patient, severity
of the disease, including the length of the
affected gut, and the biggest postopera-
tive problems are persistent constipation
and enterocolitis (Langer et al., 1996).
Genetics of Hirschsprung’s disease
The variable clinical manifestations and
inheritance of Hirschsprung’s disease sug-
gest that it is a multifactorial disorder.
Most cases are sporadic, but both autoso-
mal recessive and dominant modes of in-
heritance have been reported (Badner et
al., 1990). It has been assumed that cases
with extensive defects in the intestinal in-
nervation are more likely inherited. An
increased sex ratio (3 to 5 males: 1 female)
and an elevated risk of siblings (4%), as
compared with the population incidence
of Hirschsprung’s disease, have been re-
ported (Badner et al., 1990).
Aganglionic megacolon is not always
found as an isolated defect but is a fre-
quent finding, e.g. in Down syndrome
(Passarge 1967). Several other more or
less linked syndromes include cartilage-
hair hypoplasia, the Smith-Lemli-Opitz
syndrome type II, Waardenburg-
Hirschsprung disease, piebaldness and
primary central hypoventilation syndrome
(Ondine’s curse) (Passarge 1967; O’Dell
et al., 1987; Badner et al., 1990).
Neurotrophic factors and their receptors
are important developmental and neuronal
molecules and therefore good candidates
to be responsible for different develop-
mental and neurodegenerative diseases. In
Hirschsprung’s disease,  approximately 30
percent of the patients have mutations in
the Ret gene. GDNF is a strong survival
factor for the dopaminergic neurons that
degenerate in Parkinson’s disease. Meckel
syndrome is a severe brain malformation
that had been mapped to the same region
with the p75NTR gene. These diseases
will now be discussed in more detail.
Hirschsprung’s Disease
Clinical picture
Hirschsprung’s disease patients suffer
from severe obstipation that usually, but
not always, manifest shortly after birth
(Hirschsprung 1888). The absence of gan-
glia in the entire length or various seg-
ments of the large bowel characterizes the
disease, also termed aganglionic megaco-
lon. In addition to the lack of enteric gan-
glia, a highly increased density of cholin-
ergic nerve fibers is seen in the colonic
mucosa. The diagnosis is made by a com-
bination of tests, such as anomanometry,
radiological examinations and histologi-
cal, histochemical or immunohistochemi-
cal analyses of the affected region of the
colon (Molenaar et al., 1989; Martucciello
et al., 1998). The treatment of
Hirschsprung’s disease is the surgical re-
moval of the aganglionic segment, which
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GDNF signaling in Hirschsprung’s
 disease
In contrast to the sporadic cancers and
cancer syndromes with mutations consti-
tutively activating Ret, approximately 25
to 30 percent of patients with
Hirschsprung’s disease show mutations
inactivating the Ret signaling. These mu-
tations vary from missense or nonsense
point mutations to deletions (Pasini et al.,
1996; Edery et al., 1997) and they result
in the inactivation of the tyrosine kinase
or ligand binding domain or in the
perturbance of the membrane transport of
the receptor (Edery et al., 1994; Angrist
et al., 1995; Attie et al., 1995; Pasini et
al., 1995; Carlomagno et al., 1996; Ito et
al., 1997).
An interesting question is, why do the
Hirschsprung’s disease patients only
rarely have renal malformations? One ex-
planation is that all Ret gene mutations in
Hirschsprung’s disease described until
now have been heterozygous. This is in
accordance with the lack of a kidney phe-
notype in the Ret heterozygous mice. The
reduced number of functional Ret recep-
tors in Hirschsprung’s patients may not be
enough to affect renal morphogenesis in
man, but is enough to perturb morphogen-
esis in a less redundant organ, the intes-
tine. Also, there is no correlation between
the site and size of the mutation in Ret
gene and the extent of colonic
aganglionosis (Attie et al., 1995). This
unexpected finding may reflect modula-
tion of the clinical phenotype by unknown
genes. Some mutations in the Ret gene, in
particular those that block the transport of
the receptor to cell surface certainly re-
duce the amount of active Ret receptors
to half. Some other mutant and inactive
Ret receptors are transported to the cell
surface and could act as dominant-nega-
tive inhibitors of the wild-type receptor
(Carlomagno et al., 1996; Ito et al., 1997).
Soon after the identification of GDNF as
a ligand for Ret, many groups analyzed
the GDNF gene in a number of patients
with Hirschsprung’s disease. Only seven
patients with five different heterozygous
variants in the GDNF gene have been
found in materials including more than
300 patients (Angrist et al., 1996;
Ivanchuk et al., 1996; Salomon et al.,
1996). Some of these variants were also
found in healthy individuals and in one
family the father was homozygous for the
same variant as his affected child, but did
not have the Hirschsprung’s disease him-
self (Salomon et al., 1996). It seems that
the question of the genetics and the con-
sequences of the GDNF mutations is com-
plicated and more genes may be involved
simultaneously as the variations in both
alleles of one gene did not lead to disease
in the above mentioned family. Further-
more, biochemical analyses of these
GDNF mutations in the receptor kinetics
have not been performed.
Some alterations in Hirschsprung’s dis-
ease have been found in the gene coding
for GFRa-1, GFRa-2 (Myers et al., 1998)
and NTN (Salomon et al., 1998), but it
looks like there may not be any clear dis-
ease causing mutations.
Endothelin signaling and other genes
in Hirschsprung’s disease
Several genes in endothelin signaling have
turned out to be involved in the pathogen-
esis of Hirschsprung’s disease.
Endothelins (EDN1, EDN2 and EDN3)
form a family of small 21 amino acid pep-
tides that were discovered as potent
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smooth muscle contractors on vascular
endothelia (Yanagisawa et al., 1988; Inoue
et al., 1989). Mature endothelins are pro-
cessed from a precursor protein by the
endothelin converting enzyme 1 (ECE1)
and they mediate their effects through two
endothelin receptors (EDNRA or
EDNRB) that belong to the family of G-
protein-coupled heptahelical receptors.
EDNRB is expressed in brain, kidney,
lung, heart and endothelia, but the protein
is also found in the human colon, i.e. the
myenteric plexus, mucosal layer, ganglia
and blood vessels of the submucosa
(Inagaki et al., 1991; Sakamoto et al.,
1991).
EDNRB was the affected gene in a previ-
ously mapped susceptibility locus of a re-
cessive form of Hirschsprung’s disease
(Puffenberger et al., 1994) and a specific
missense mutation W276C predisposed to
the disease. This mutation was first found
in a consanguineous pedigree, and it was
dosage sensitive. W276C homozygotes
and heterozygotes had a 74% and a 21%
risk of developing Hirschsprung’s disease,
respectively. Other heterozygous muta-
tions both in syndromatic and isolated
Hirschsprung’s disease as well as in non-
consanguineous populations have later
been found (Attie et al., 1995; Amiel et
al., 1996; Auricchio et al., 1996). The next
disease gene for Hirschsprung’s disease
was endothelin 3 (EDN3), the gene encod-
ing the ligand for EDNRB (Edery et al.,
1996; Hofstra et al., 1996). These muta-
tions are homozygous and were first found
in a syndrome resulting in a widespread
developmental failure of neural crest de-
rivatives, the combined Waardenburg-
Hirschsprung disease (Shah-Waardenburg
syndrome) with aganglionic megacolon,
sensoryneural hearing loss and pigmen-
tary anomalies. A heterozygous EDN3
mutation has been found in isolated
Hirschsprung’s disease (Bidaud et al.,
1997) and one ECE1 mutation has also
been described recently (Hofstra et al.,
1998).
Several mouse models have helped the
search for Hirschsprung’s disease genes
and the pathogenesis of aganglionosis. In
addition to the GDNF and Ret knockout
mice, there are several natural mutant lines
with failures in the neural crest cell mi-
gration. They show Hirschsprung –like
aganglionic megacolon and, in some lines,
also the absence of melanocytes in the
skin. The alleles of lethal spotted (ls) and
piebald lethal (sl) (Lane 1966) in natural
mutant mouse strains code for the
endothelin 3 (Baynash et al., 1994) and
endothelin receptor b (Hosoda et al.,
1994), respectively. A third strain of
Dominant megacolon mice has a mutation
in the Sox 10 gene that encodes for an
SRY-like transcription factor (Southard-
Smith et al., 1998). Very recently, patients
with Shah-Waardenburg syndrome with
aganglionic megacolon, pigmentary
anomalies and sensoryneural deafness,
were shown to have a mutation in the
SOX10 gene (Pingault et al., 1998).
Parkinson’s Disease
Parkinson’s disease is a common
neurodegenerative disorder with a
prevalence of approximately 1-2% in
the population over 50 years of age. The
patients suffer from resting tremor,
bradykinesia, rigidity and postural in-
stability that is caused by the progres-
sive loss of dopaminergic neurons in the
substantia nigra. The pathogenesis of
Parkinson’s disease is unclear, although
several hypotheses exist. The neuronal
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Most of the studies of GDNF in
Parkinson’s disease have been performed
in animals. There are multiple ways of
creating animal models for these studies
by damaging the midbrain dopaminergic
neurons in rodents or primates. The tox-
ins 6-hydroxydopamine (6-OHDA)
(Simon et al., 1974) or 1-methyl-4phenyl-
1,2,5,6-tetrahydropyridine (MPTP)
(Heikkila et al., 1984) have been mostly
used to create parkinsonism that especially
in primates resemble the human disease
in great detail. These animal models have
then been used to look for and study the
molecules that would protect, support or
even cure the symptoms. In these kinds of
experiments, GDNF has proved to be the
most potent neuroprotective factor in vivo
by preventing and rescuing the dopamin-
ergic neurons from degeneration and re-
lieving the symptoms even after neuronal
damage (Lin 1996; Lapchak et al., 1997))
(Table 5). The level of GDNF seems to be
critical for the survival of the neurons,
which suggests that GDNF could be used
in the prevention of the progression of
Parkinson’s disease.
Meckel syndrome
Meckel syndrome is a lethal autosomal
recessive syndrome characterized by an
occipital meningoencephalocele, large
multicystic kidneys, fibrotic changes of
the liver and postaxial polydactyly
(Salonen and Paavola, 1998). The clini-
cal features are variable and include addi-
tional anomalies, like cleft palate, congeni-
tal heart defects, club feet and ocular
anomalia (Salonen 1984). The prevalence
of Meckel syndrome in Finland is 1:9000
(Salonen and Norio, 1984), but  it varies
in different populations from 1:1300 in
Gujarati Indians to 1:50 000 in Israeli Jews
loss has been proposed to occur be-
cause of oxidative stress due to free
radicals, environmental factors such as
1 - m e t h y l - 4 - p h e n y l - 1 , 2 , 3 , 6 -
tetrahydropyridine (MPTP), amino
acid or calcium toxicity (Temlett
1996).
The first identified Parkinson’s disease
gene seems to be alpha-synuclein, cod-
ing for a presynaptic protein that is de-
fective in a familial form of the dis-
ease  (Polymeropoulos et al., 1997). A
second susceptibility locus has been
found in the chromosome 2p13 (Gas-
ser et al., 1998) and a gene responsible
for a rare recessive form of juvenile
parkinsonism has been identified
(Kitada et al., 1998). These genes are
unlikely to play a common pathogenic
role in Parkinson’s disease since no
mutations have been found in the spo-
radic forms of the disease. The normal
functions of alpha-synuclein and the
novel gene, parkin, are not known.
Many efforts have been performed to
identify gene mutations in Parkinson’s
disease, but these have led only to ex-
clusions of some candidate genes, like
superoxide dismutase and catalase
(Parboosingh et al., 1995).
GDNF in Parkinson’s disease
The level of GDNF mRNA in the adult
CNS seems to be very low in both
Parkinson’s patients and controls (Hunot
et al., 1996), and the GDNF protein lev-
els or even its function in the adult hu-
man brain are not known. Furthermore,
the dopaminergic cells of Parkinson’s
disease patients are difficult to study be-
cause most of them are lost during the
disease process.
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(Salonen and Paavola, 1998). Although
Meckel syndrome is clearly a recessive
disorder, some reports suggest also a
milder heterozygous phenotype in the rela-
tives of the patients (Salonen and Norio,
1984; Gulati et al., 1997).
The gene causing Meckel syndrome is not
known. In 17 Finnish families the gene
locus was mapped to chromosome 17q21-
q24 (Paavola et al., 1995) to the close vi-
cinity of the p75NTR gene. This region
has been excluded in some other families
(Paavola et al., 1997; Roume et al., 1997),
suggesting genetic heterogeneity.
Meckel syndrome is recognized often in
rutine mid-gestation ultrasound screening
and the diagnosis is verified by autopsy
after the termination of the pregnancy. The
high-risk families that already have had
affected children can be scanned at 11-12
weeks of pregnancy by vaginal ultrasound
(Sepulveda et al., 1997). In families with
established linkage to 17q21-q24, the pre-
natal diagnosis of Meckel syndrome can
be done by DNA analysis.
The pathological anatomy and histology
of Meckel syndrome patients have been
thoroughly studied in different tissues and
the similarity of findings in multiple or-
gans (Rapola and Salonen, 1985; Rapola
1989) suggest a failure in inductive inter-
actions during the development. The genes
coding for developmental factors ex-
pressed in the affected tissues are there-
fore interesting Meckel syndrome candi-
date genes. One of these candidates
mapped in 17q21-q24, the p75NTR gene,
is expressed in the brain, kidney, testis and
ovaries and is also critically involved in
nephrogenesis (Buck et al., 1987; Sariola
et al., 1991).
Table 5. GDNF rescue studies in animal models for Parkinson’s disease.
Lesion type Rescue method Result References
6-OHDA in
rat: injections
uni- or
bilaterally
GDNF-injections
intranigrally or
GDNF adenoviral
transfection
dopaminergic
neurons
restored,
symptoms
decreased
(Hoffer et al., 1994; Kearns
and Gash, 1995; Sauer et al.,
1995; Bowenkamp et al.,
1997; Choi-Lundberg et al.,
1997)
Axon
transection in
rat
Daily intranigral
GDNF-injections
dopaminergic
neurons restored
(Beck et al., 1995)
MPTP in
mouse:
subcutaneous
injections
GDNF-injection
intrastriatally or
intranigrally before
or after MPTP
dopaminergic
neurons restored
(Tomac et al., 1995)
MPTP in
rhesus
monkey:
carotid artery
infusion
GDNF- injection
intracerebrally,
intracaudally or
intranigrally every
four weeks
dopaminergic
neurons restored,
symptoms
decreased
(Gash et al., 1996)
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STRATEGIES FOR THE IDENTIFICATION OF DISEASE
GENES
mal model for the disease and/or mice with
targeted disruption of the candidate gene.
3) The gene is conserved during evolu-
tion. The candidate gene approach is also
powerful in the search for inherited dis-
ease genes, when the disease locus has
been assigned by positional cloning.
Finding the candidate genes will become
easier in the future, with the advance in
the Human Genome Project (http://
www.nhgri.nih.gov/HGP/). This world-
wide research effort is to characterize the
structure of the human genome by se-
quencing and mapping. The project is also
to characterize the genomes of yeast,
worm, fruit fly and mouse parallel with
the human studies, which gives more in-
formation of the function and evolution
of the genes.
Mutation identification
In some diseases, such as cancer, the usual
genetic event is a translocation or a dele-
tion of several hundreds to millions of base
pairs which can be identified by compara-
tive genomic DNA hybridization or  in
Southern or Northern hybridization from
DNA or RNA, respectively, with a candi-
date cDNA as a probe. In many inherited
and sporadic developmental disorders, the
disease causing mutation changes only one
nucleotide and must therefore be detected
by using more sensitive methods (Cotton
1997; Aaltonen, 1998).
There are many possible ways to search
for genetic associations and gene alter-
ations in diseases. Chromosomal abnor-
malities can be visualized with a micro-
scope from a metaphase cell preparation,
but in most cases the alterations are only
minor and need molecular genetic meth-
ods to be found (Foroud 1997). In a clas-
sical disease gene mapping project, the
locus of an inherited disease gene is first
assigned to a chromosomal region with
microsatellite markers, after which the
search for the gene itself is started. The
disease gene is then identified by narrow-
ing the size of the target region, by posi-
tional candidate approach or systemati-
cally by physical mapping and analyzing
all the genes in that area.
Candidate genes
Most diseases are not inherited, or the in-
heritance pattern  is so complicated that it
cannot be easily observed. In these spo-
radic or complex and multigenic diseases,
the positional cloning method is less effi-
cient or impossible, and the identification
of disease genes is often based on a can-
didate gene approach that is based on the
functional and expression data of the gene.
The possibility of finding a disease gene
by this approach depends on the informa-
tion that is available of the candidate gene
that can be compared with the pathology
or pathophysiology of the human disease.
The optimal situation is if: 1) The struc-
ture, function and expression of the can-
didate gene are known. 2) There is an ani-
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The methods for detecting point mutations
are usually based on polymerase chain
reaction (PCR) and they can be divided
into three categories: 1) Direct sequenc-
ing. 2) Aberrant migration of the mutant
PCR product. 3) Enzymatic cleavage in a
mismatch heteroduplex molecule. When
choosing which method to use, the advan-
tages and disadvantages of each alterna-
tive must be weighed (Cotton 1997). The
direct sequencing of the PCR product is
most informative, but it is also the slow-
est and most expensive of the three meth-
ods. This is likely to change in the future
when the DNA “chip” technique is ad-
vanced (Southern 1996). The methods
monitoring the aberrant migration of the
mutant PCR product amplified from the
patient template include single strand con-
formation polymorphism (SSCP) (Orita et
al., 1989), denaturing gradient gel elec-
trophoresis (DGGE) (Myers et al., 1987)
and heteroduplex analysis (HA)
(Nagamine et al., 1989). These methods
are fast but they are not 100% sensitive
and the mutation has to be identified by
sequencing the samples with altered mo-
bility. These same disadvantages are found
also in the third category of the mutation
detection methods, although they are more
sensitive, allow the screening of longer
fragments and give a rough estimate of the
location of the mutation in the sample.
These approaches include the RNase A
cleavage, chemical cleavage, enzyme mis-
match cleavage and cleavase fragment
length polymorphism (CFLP) methods
(Cotton 1997).
Mutation-disease correlation
The consequences of a certain sequence
variant or its role in a disease pathogen-
esis is sometimes difficult to determine.
A nonsense or frameshift mutation that
leads to a truncated protein, most likely
disrupts the gene function, but a gene with
a missense point mutation can be totally
functional. The importance of a certain
amino acid to the gene function can be
estimated by comparing the conservation
of the residue between different species
during evolution. In inherited diseases, a
strong evidence for a causative genetic
change is the segregation of the mutation
with the disease phenotype and the ab-
sence of the variation in controls. Func-
tional test for the mutant gene would be
most informative to find out the conse-
quence of the variation, but they are often
not feasible.
The allele frequency of the identified
variation can be determined in a large
number of normal and affected samples
by sequencing, restriction fragment analy-
sis or for example by “minisequencing”
pools of DNA from a number or individu-
als (Syvänen et al., 1993). However, in
more complicated genetics where a dis-
ease is multigenic, has a low penetrance
or may display several modes of inherit-
ance one has to be careful with the inter-
pretation of allele frequency analyses. As
has been seen in the genetics of
Hirschsprung’s disease, the segregation of
the disease with the mutation does not
necessarily prove the mutation to be caus-
ative for the disease. On the other hand, a
variation can be a disease associated mu-
tation even without being necessary for the
disease phenotype or sufficient to cause
the disease alone (Salomon et al., 1996).
These genes could be called disease-as-
sociated with major or minor modifying
sequence variants - factors that we are
going to run into now when the genetics
of complex disorders is starting to be re-
vealed (Hofstra et al., 1997).
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AIMS
The aims of this thesis were to study the biology and pathology of the genes involved
in neurotrophic signaling. We wanted to characterize the function of these develop-
mentally important factors in more detail and to study their possible roles in diseases.
The specific aims of this work were:
1. To identify and characterize receptor(s) for GDNF
2. To study the expression and function of GDNF and its receptors in the developing
gut and kidney
3. To search for mutations in the GDNF gene in diseases that are closely linked to its
function: Hirschsprung’s disease, renal agenesis and Parkinson’s disease.
4. To search for mutations in the p75NTR gene in Meckel syndrome
MATERIALS AND METHODS
Cloning of human GDNF
The cDNA for human GDNF was cloned
by RT-PCR from the fetal brain RNA and
ligated to TA cloning vector (Invitrogen)
according to manufacturer’s protocol.
Several clones were grown, isolated and
sequenced in both directions.
Cloning of human and rat GFRa-2
cDNA
Several human clones similar to GFRa-1
were found in the EST database search.
The rat cDNA was cloned from adult rat
hippocampus library and the 5’-end of the
human cDNA was amplified by PCR from
human fetal cDNA. The cloning proce-
dures are described more in detail in (II).
Probes
The probes for in situ and Northern hy-
bridizations of human samples were syn-
thesized from cDNA inserts of human
GDNF (636 bp), GFRa-1 (2537 bp, a kind
gift from Dr. G.Fox, Amgen), GFRa-2
(1490 bp) and mouse ret (714 bp) clones.
The probes for FISH were the human 1490
bp GFRa-2 cDNA and a mouse 10 kb
genomic fragment containing the initia-
tion ATG-codon.
Fluorescent in situ hybridization
The fluorescent in situ hybridization of
metaphase chromosome lymphocytes was
performed using the 1490bp human cDNA
and 10kb mouse genomic probes as de-
scribed in (II).
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Northern analysis
The detection of the GFRa-2 mRNAs
from different human tissues was done by
hybridizing  radiolabeled GFRa-2 probe
to Human and Human Fetal Multiple Tis-
sue Northern Blot filters as described in
(II).
Growth factors and antibodies
Human recombinant GDNF was pur-
chased from Promega and PeproTech Inc.
Baculovirus -produced rat GDNF was a
gift from Dr. Carlos Ibáñez. The antibod-
ies to Ret and phosphotyrosine were from
Santa Cruz and Transduction Laborato-
ries, respectively.
Receptor tyrosine phosphorylation
assay
The immunoprecipitation and Western
blotting of the Ret protein with anti-Ret
and anti-phosphotyrosine antibodies are
described in detail in (I) and (II).
Sample tissues
The tissues of patients were taken from
autopsy or blood samples with the full
ethical permission of the patents or the
hospital in question (Hospital for Children
and Adolescents in Helsinki, Karolinska
Institutet in Stockholm and Turku Univer-
sity hospital). The tissues were treated as
described in (III-V).
In the animal experiments tissues from
Sprague-Dawley and Wistar rat and mouse
embryos were used. In these experiments,
the animals were mated overnight and the
next day was defined as embryonic day 0
(E0).
p75NTR immunohistochemistry
Mouse antibodies to human p75NTR
(Boehringer) were used at 1:10 dilution
to stain acetone-fixed cryosections of pla-
centa, kidney and spleen of 3 Meckel syn-
drome patients and 3 age-matched controls
(V). The staining was visualized by FITC-
conjugated antibodies to mouse IgG.
In situ hybridization
In situ hybridization was performed as
described (Wilkinson and Green, 1998),
with slight modifications (Kallunki et
al., 1992) that are described in (III and
IV).
RT-PCR
The extraction of polyA mRNA from the
fetal and newborn colon, and the RT-PCR
protocol are described in more detail in
(III).
Cell and organ cultures
The tissues for organ cultures were
microdissected and cultured in Trowell-
type dishes as described in (IV).
SSCP analysis
SSCP analysis with the radiolabeled PCR
fragments was performed as described
(Orita et al., 1989) with some modifica-
tions (Suomalainen et al., 1992).
Mutation search by sequencing
The sequencing of direct PCR fragments
and their cloned inserts of patient samples
were done in the DNA synthesis and se-
quencing core-facility of the Institute of
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Biotechnology. Different samples were
sequenced either in ALF or ABI sequenc-
ers according to the current protocol for
either solid-phase or cycle sequencing.
Minisequencing
The mutation frequency analysis by
minisequencing was performed as de-
scribed (Syvanen et al., 1993).
Radiation hybrid mapping
Radiation hybrid mapping panel provided
by Research Genetics was utilized to or-
der the genes of NGFR and HOXB6 as
well as the polymorphic microsatellite
markers D17S806, D17S1607, D17S957,
and D17S807 as described in (V). Radia-
tion hybrid mapping data was analyzed
RESULTS AND DISCUSSION
using multipoint maximum likelihood
approach and the FORTRAN programs
RH2PT and RHMAXLIK from the pack-
age RHMAP version 2.01 (Boehnke et al.,
1991). In multipoint analysis we carried
out branch and bound strategy assuming
equal fragment retention as well as allow-
ing centromeric effect. Breakage prob-
abilities theta were converted to additive
distances d (cR) according to the formula
d = -ln(1-theta ) (Cox et al., 1990).
CFLP analysis
CFLP mutation analysis of the GDNF
gene PCR products of the Parkinson’s dis-
ease patients was done according to
manufacturer’s (Boehringer Mannheim)
protocol.
Ret mediates GDNF signal in meso-
derm induction of the Xenopus
blastula animal caps (I)
The animal cap cells of blastula-stage Xe-
nopus embryo give rise to epidermal tis-
sue, if untouched. However, the activation
of the mitogen activated protein kinase
(MAPK) is sufficient and necessary to in-
duce the mesoderm in these cells
(Umbhauer et al., 1995). The injection of
in vitro synthesized RNA of a constitu-
tively active Ret receptor (Ret C634R) that
signals through the MAPK led to the me-
soderm induction, while wild type Ret or
GDNF RNA injections alone did not. The
mesoderm induction, defined by morpho-
logical, histological and molecular mark-
ers was however gained by co-injecting
the mRNAs of wild type Ret and GDNF,
suggesting that GDNF activates Ret sig-
naling. This result was specific for Ret, as
another tyrosine kinase Sek1, co-injected
with GDNF mRNA, did not induce the
mesoderm. Further support of the GDNF
signaling through Ret was obtained by
chemical crosslinking studies.
In addition to the biological assay de-
scribed above, several groups simulta-
neously reported the interaction between
GDNF and Ret (Jing et al., 1996; Treanor
et al., 1996; Trupp et al., 1996; Vega et
al., 1996). Also another receptor for Ret,
GFRa-1 (previously GDNFRa) was iden-
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tified and shown to be the high-affinity
binding co-receptor for GDNF (Jing et al.,
1996; Treanor et al., 1996).
The finding of tyrosine kinase receptor Ret
as a functional receptor for GDNF was
unexpected, because all previously known
TGFb family members bind to serine-
threonine kinases (Josso and di Clemente,
1997). These results do not rule out the
possibility that GDNF could interact with
alternative, serine-threonine kinase recep-
tors.
Cloning and characterization of the
GFRa-2 gene (II)
The initial cloning of GFRa-2 (formerly
GDNFRb) was done by searching the Ex-
pressed Sequence Tag (EST) database
with the sequence of GFRa-1 as a probe,
which identified eight human sequences
from six different clones. These clones
were sequenced to form a contig of 1032
bp of human GFRa-2 cDNA. The rat
cDNA was then cloned from the rat hip-
pocampal cDNA library and the 5’end of
the human gene was amplified from hu-
man fetal brain cDNA.
The GFRa-2 gene was found to be a close
homolog to GFRa-1 with 48% identity at
the predicted amino acid level. All the
cysteine residues are conserved which
suggests a similarity in the tertiary struc-
ture. GFRa-2 has a signal sequence, three
N-glycosylation sites and a putative gly-
cosyl-phosphatidylinositol anchor site
similar to GFRa-1. The loci of the GFRa-
2 gene were assigned to the human chro-
mosome 8p21-p22 and to a correspond-
ing region in the mouse chromosome
14D3-E1 by fluorescent in situ hybridiza-
tion (FISH).
Expression and function of GFRa-2
(II)
By northern hybridization we found two
major GFRa-2 transcripts of 3.5 and 2.9
kb that were expressed in human adult
brain, intestine, placenta and fetal kidney.
Additional transcripts of 7.5 kb and 1.4
kb were also visible in placenta and testis,
respectively. The in situ hybridization of
GFRa-2 and GFRa-1 showed non-over-
lapping mRNA distribution in several or-
gans of the rat E17 embryo. GFRa-2
mRNA was seen in the capsule and cor-
tex of adrenal gland, the undifferentiated
nephrogenic mesenchyme of the kidney
and vaguely in the enteric plexuses of the
small intestine. GFRa-1 mRNA was seen
in the adrenal medulla, in the tips of ure-
ter buds and strongly expressed along the
gastrointestinal tract where GFRa-2 was
not or was only weakly expressed.
The ability of GFRa-2 to mediate GDNF-
induced activation of Ret was analyzed by
transfecting the COS-7 cells with the
cDNAs encoding GFRa-1, GFRa-2 and
Ret in different combinations. The
transfection of either GFRa-1 or GFRa-2
in combination with Ret resulted in Ret
phosphorylation after GDNF treatment,
which indicated that GDNF can bind to
and signal through a Ret/GFRa-2
complex.
Several groups simultaneously reported
the GFRa-2 gene with different names.
The name of GFRas is the consensus of
the nomenclature committee (GFR-alpha
nomenclature committee 1997) that
ceased the use of TGF-b related
neurotrophic factor receptor 2 (TrnR2)
(Baloh et al., 1997), Ret ligand 2 (RetL2)
(Sanicola et al., 1997), neurturin receptor
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a (NTNRa) (Buj-Bello et al., 1997; Klein
et al., 1997) and GDNF receptor b
(GDNFRb) (II).
These studies confirmed the function of
GFRa-2 in Ret activation and suggested
that the preferred ligands for GFRa-1 and
GFRa-2 are GDNF and NTN, respectively
(Baloh et al., 1997; Buj-Bello et al., 1997;
Klein et al., 1997), although both GFRa-
1 and GFRa-2 can bind both ligands. The
mechanism of GFRa-1 and GFRa-2 to
mediate Ret activation is different, since
GFRa-1 first binds to GDNF and then to
Ret (Jing et al., 1996), but GFRa-2 does
not form complexes with GDNF in the
absence of Ret (Sanicola et al., 1997).
Distribution of GDNF and its recep-
tors in the developing human gut (III)
By in situ hybridization we found that
GDNF mRNA expression was abundant
in the muscularis mucosae of both fetal
Figure 4.
Upper: Bright (A,C,E) and dark (B,D,F) field images of GDNF in situ hybridization showing
mRNA in the muscularis mucosae (MM) of colon in fetus (A,B) and newborn (C,D). The
ganglia (GA) are negative (E,F). Lumen (LU) and circular muscle (CM) are marked. Lower:
RT-PCR results confirming the higher level of GDNF mRNA  in the colon compared to the
ileum. For details see (III).
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and newborn human colons (Figure 4). In
contrast to a recent immunohistochemi-
cal study (Bär et al., 1997), GDNF mRNA
was neither found in the neural plexuses
nor in other regions of the intestine. The
previous results may reflect the localiza-
tion of the bound GDNF to the neurons or
the distribution of other GDNF-family
ligands, such as NTN crossreacting with
the polyclonal antibody rather than the site
of GDNF synthesis assayed by us. We
found by reverse transcription-PCR that
GDNF mRNA level was many folds
higher in the colon than ileum (Figure 4),
which is in accordance with the GDNF
expression pattern found by in situ hybrid-
ization.
Our results by in situ hybridization and
reverse transcription-PCR show that, in
human, GDNF mRNA expression is abun-
dant in the colon but very low in the il-
eum from gestational week 25 to newborn,
a pattern that has not been found in the
animal studies. The muscularis mucosae
of rodents consists of only a few cell lay-
ers, and their entire enteric muscle layer
is only slightly thicker than the human
muscularis mucosae. These anatomical
and scale differences between species may
account for the differences in the distri-
bution of GDNF. We cannot exclude the
possibility that GDNF could have a wider
distribution in earlier developmental
stages, but our results suggest a major role
for the muscularis mucosae, and GDNF
derived from it, in the development of the
innervation of the human colon at gesta-
tional week 25 and thereafter. The selec-
tive distribution of GDNF mRNA suggests
critical roles for the muscularis mucosae
in intestinal innervation. To our knowl-
edge, GDNF is the first growth factor se-
creted by the muscularis mucosae.
By in situ hybridization we also found the
Ret, GFRa-1 and GFRa-2 mRNA expres-
sion in the ganglionic cells of both myen-
teric and submucosal plexuses throughout
the intestine. Interestingly, Ret and GDNF
family receptors mRNAs were expressed
also in the enteric segments where GDNF
mRNA could not be detected. This sug-
gests that the innervation of the gut may
be affected, in addition to GDNF, by other
growth factors like NTN that bind to these
receptors. NTN mRNA expression in the
mouse intestine has been analyzed by RT-
PCR (Widenfalk et al., 1997), but at
present no expression data of NTN in hu-
man or its relationship to Hirschsprung’s
disease has been reported.
A second signaling receptor for GDNF or
NTN has been suggested based on the ex-
pression data (Suvanto, 1997) and the dif-
ferences in the kidney phenotypes of
GDNF and Ret –deficient mice. A second
functional receptor for the GDNF family
growth factors would also fit nicely with
the current molecular genetic data from
Hirschsprung’s disease, where approxi-
mately half of the patients have no genetic
explanation for their disease.
GDNF is required for ureteric bud-
ding in kidney development (IV)
In the cultures of E11 mouse urogenital
blocks, the GDNF –soaked agarose beads
caused supernumerous budding from the
Wolffian duct. The beads distorted the
branching pattern of the connecting tu-
bules in cultures of late kidneys. Some
growth factors like HGF (Davies et al.,
1995) and TGF-b1 (Ritvos et al., 1995)
induce the proliferation of ureteric cells
and promote the elongation of the
branches but these growth factors were not
able to induce the budding from the Wolf-
fian duct. The GDNF-releasing beads did
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not induce budding from the Wolffian
ducts of the Ret-deficient mice. Because
GDNF is expressed in the nephrogenic
mesenchyme, these data show that the
branching of the ureter from the Wolffian
duct is mesenchyme –dependent.
If the ureteric bud is recombined with het-
erologous mesenchymes, no branching is
observed. In the recombination cultures
with ureteric buds and heterologous mes-
enchymes supplemented with GDNF, only
rat lung and kidney mesenchymes sup-
ported the branching. However, the growth
or branching was not supported by sali-
vary gland, limb bud or teeth bud mesen-
chymes. These data suggest that in addi-
tion to GDNF, some other mesenchymal
molecules are required for the growth and
branching of the ureter epithelium.
p75NTR in Meckel syndrome (V)
By immunohistochemistry, we found an
identical distribution of immunoreactive
p75NTR protein in embryonic kidneys,
spleen and placenta of Meckel syndrome
patients as compared to age-matched con-
trols.
The SSCP (Figure 5) and sequence analy-
sis revealed a heterozygous C->T substi-
tution predicted to result in a Ser-> Leu
amino acid change in the exon 4 in two
Meckel syndrome patients and one carrier.
We determined the prevalence of this
polymorphism by minisequencing DNA
pools representing the Finnish population
to be approximately 10 (20/ 200) percent
which was too big compared with the
1:9000 incidence of Meckel syndrome
(Salonen and Norio, 1984) in Finland. No
other nucleotide variations were found in
the p75NTR gene in Meckel syndrome
patients and the radiation hybrid panel fi-
nally located the NGFR gene outside the
Meckel syndrome locus. Subsequently,
the locus in Finnish Meckel syndrome
patients has been refined to a less than 1
cM on chromosome 17q22 (Salonen and
Paavola, 1998), and it is clear that p75NTR
is not the causative gene for this syndrome.
The heterozygous polymorphism was not
studied further. However, it would be in-
teresting to study its biochemical effects,
since it affects the important transmem-
brane region of the molecule. Based on
the allele frequency, there are most likely
a number of homozygous individuals for
the mutation in the Finnish population. At
the moment, no other inherited disease has
Figure 5.
Single strand conformation polymorphism
(SSCP) autoradiograph  showing the
aberrant migration of the PCR fragment
amplified from  mutated p75NTR exon
four in one patient (p4). Double strand (ds)
and wild type (wt) controls are marked.
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been mapped to the vicinity of the
p75NTR gene that could be considered as
a candidate disease for this developmen-
tally interesting gene.
GDNF mutation analysis in
Hirschsprung’s disease and renal
agenesis (unpublished)
Soon after the identification of Ret as the
functional receptor for GDNF, we
screened the mature protein coding region
of the GDNF gene from the samples of 35
non-familial Hirschsprung’s disease pa-
tients by PCR and direct sequencing.
Based on the results of the importance of
GDNF to the kidney development (Pichel
et al., 1996) we also sequenced the
samples of two families with a history of
renal agenesis in two individuals from
which frozen tissue was available. We did
not find any alterations of the GDNF gene
in these patients.
In other studies (Angrist et al., 1996;
Ivanchuk et al., 1996; Salomon et al.,
1996) comprising of more than 300 pa-
tients, five different variants in the entire
coding region of the GDNF gene was
found in seven patients. This indicates that
the rate of GDNF mutations in
Hirschsprung’s disease is low, which is
in accordance with our negative results
from a relatively small number of patients.
 Renal agenesis is a relatively common
solitary malformation with only rare re-
lapses in later pregnancies. It is included
in a number of different syndromes, but
little is known of its genetics, although
there are more than 30 mouse strains with
renal dysplasia or aplasia (the kidney da-
tabase, 1998). Several patients with com-
bined unilateral kidney aplasia and
Hirschsprung’s disease have been studied
but no data of mutations in the GDNF sig-
naling cascade has been presented thus far
from patient with renal agenesis. Also our
data from two patients is not sufficient to
exclude GDNF gene mutations in the
pathogenesis of renal aplasia.
GDNF mutation analysis in
Parkinson’s disease (VI)
There is strong evidence from animal ex-
periments that GDNF protects the dopam-
inergic system neurons from cell death.
At the moment there are no data about the
levels of GDNF either in the normal or
affected human brain but it would be logi-
cal to assume that the decreased levels of
GDNF would result in poor survival of the
dopaminergic neurons and could be a pre-
disposing factor for Parkinson’s disease.
Some of the carriers of heterozygous
GDNF mutations develop normally
(Salomon et al., 1996) and we postulated
that these individuals might be enriched
within the patients of Parkinson’s disease.
The coding region of GDNF gene was
analyzed from 30 Parkinson’s disease pa-
tients from whom we found a novel GDNF
sequence variant in one patient by CFLP
analysis and direct sequencing. The alter-
ation does not change the predicted amino
acid sequence or RNA folding and it was
also found in one out of 20 patients with-
out Parkinson’s disease, suggesting that
it represents a polymorphism in the gene
rather than a disease-associated mutation.
No other sequence variations were found
and we concluded that GDNF mutations
are not common in the sporadic form of
Parkinson’s disease. In our study we did
not find any of the previously described
GDNF mutations (Angrist et al., 1996;
Ivanchuk et al., 1996; Salomon et al.,
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1996) which might reflect the Finnish ge-
netic background that somewhat differs
from the rest of the world.
As described earlier, there is little evidence
of a genetic contribution to most cases of
Parkinson’s disease (Nussbaum 1998).
However, our negative mutation finding
does not rule out the possible function of
GDNF as an anti-Parkinson’s factor. It
would be interesting to analyze the GDNF
protein levels and its functionality, but at
present it does not seem feasible because
of the low level of GDNF in the adult
brain. Also the RNA analysis could be
informative as Alzheimer’s and Down
syndrome patients were recently shown to
have frame shift mutations only in the
RNA level that were not detected in ge-
nomic DNA (van Leeuwen et al., 1998).
Despite the great neuroprotective potency
of GDNF shown in the animal experi-
ments, the possible use of GDNF or any
other neurotrophic peptide in the treatment
of human patients seems distant at this
point. In the animal experiments GDNF
has to be adjusted parentally or even in-
tracerebrally to avoid its degradation. In
humans this kind of treatment would be
difficult or impossible. Instead of using
the polypeptides or vectors producing pep-
tides, a goal in the pharmaceutical research
is to create small molecules that mimic
the actions of GDNF. From this point of
view it would be important to know what
are the intracellular signaling cascades
downstream of GDNF and what are the
possible ways to interfere with these
mechanisms in neurodegenerative disor-
ders, like Parkinson’s disease.
CONCLUDING REMARKS
In this study, we characterized the
functional receptors of GDNF and studied
the biology of these neurotrophic signaling
molecules in development. These and
previous findings led us to the mutation
analysis of GDNF and p75NTR genes as
candidates for different diseases, but no
disease causing mutations were found.
However, we found several genetic
alterations some of which could be studied
further.
Our study is a part of ongoing change in
genetics applied to medicine. In general,
as the genetics of sporadic or multigenic
diseases even more complex than
Hirschsprung’s disease are being studied,
we need to understand the genotype-
phenotype correlation better. To get to that
point we need to understand the
developmental function of genes and
gather all the genetic information little by
little in different multigenic diseases, by
using the candidate gene or allelic
association approach. This work will
become easier with new and faster
techniques such as DNA chip technology
and will probably reveal rules how to
interpret the consequences of a detected
mutation in multigenic or sporadic
diseases.
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